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Use of Somatostatin Analog SMS 201-995 in Medullary
Thyroid Carcinoma
Alfonso Lihroia,* Uberta Verga,* Gianleone Di Sacco,* Marco Piolini,* and
Fabrizio Muratori*

We have studied seven subjects with medullary thyroid carcinoma. Each had elevaled basal serum
calcitonin (CT) levels following lotal thyroidectomy. After subcutaneous administration of 100 \i,g of
SMS 201-995, blood samples were collected al 60-minute intervals for six hours. Two patients showed
a marked decrease of CT levels (patient A: baseline 565 pglmL, nadir 150 pglmL; patient B: baseline
1,632 pglmL, nadir 416 pglmL). The other five patients showed no significanl change in comparison
with .saline infusion. Two patients were treated with SMS 201-995 (300 \kglday)for 90 days. One of
these patients responded to the acute SMS 201-995 test and had CT levels persistently 50% lower lhan
pretreatment values during this 90-day period. The other patient, whose CT levels did nol decrease
during the acute test, had persistently high values during this 90-day period but had relief of watery
diarrhea even after the therapeutic trial was discontinued. (Henry Ford Hosp MedJ 1989:37:151-3)

M

edullary thyroid carcinoma (MTC), first described by
60,120,180, 240, 300, and 360 minutes. On the second day, the
Hazard et at (1), develops from thyroid parafollicular cells
subjects received 100 |jLg of SMS 201-995 subcutaneously at
or C-celts and secretes calcitonin (CT) (2), MTC occurs in spotime 0.
radic and occasionally in hereditary forms as multiple endocrine
neoplasia type 2 (3). Measurement of plasma CT is important
SMS 201-995 chronic treatment
for the diagnosis of MTC. Secrerion of CT is influenced by a
Two patients who had had total thyroidectomy for MTC and
variety of substances. Somatostatin, found in some C-celts (4),
persistentiy high basal CT tevels were treated with SMS 201-995
has been reported to inhibit basal and stimulated CT secretion
(300 p,g/day) for 90 days. One patient, a 68-year-old man with
from MTC cells (5), suggesting a possible paracrine relationship
persistently etevated basal CT levels (650 pg/mL), was
between the two. Because of its ultrashort half-life, the native
asymptomatic and had responded to the acute test with SMS
somatostatin-14 peptide is not useful clinically. However, so201-995 for CT. The other patient, a 58-year-old man, did not
matostatin analogs developed recently can be used clinically.
respond to the acute SMS 201-995 test. He had watery dianhea
Bauer et al (6) developed a somatostatin analog, code-named
(eight to ten episodes daily) and showed normal values of fasting
SMS 201-995 (octreotide, Sandostatin), and several reports have
plasma pancreatic polypeptide (PP), vasoactive intestinal polyshown that acromegalic patients respond favorably to chronic
peptide (VIP), and gastrin and 5-hydroxyindotacetic acid
treatment with SMS 201-995 (7). We have recently reported that
(5HtAA) urinary excretion. His PP response to secretin was
acute administration of SMS 201-995 (Sandostarin, Sandoz
physiological.
Phannaceuticals, Milan, Italy) decreased CT levels in some paThe quantitative determination of CT in seram was perfonned
tients with MTC (8). The aim ofthe present study was to evaluate
using
a radioimmunoassay method (RIA-MAT-Catcitonin I I ,
the acute effect of SMS 201-995 on CT plasma levels in patients
Byk-Santec
Diagnostica, Dietzenbach, RFA).
with MTC and its possibte rote in the chronic treatment of patients with recunent disease after totat thyroidectomy.

Results
Methods
Seven patients, two females and five mates, were included in
the study. One had hereditary MTC and six had a sporadic form.
Each had undergone total thyroidectomy and had elevated semm
CT concentrations postoperatively.
SMS 201-995 acute test
On the first day, the fasting pafients received a saline infusion
over a six-hour period. Blood samples were obtained at - 30,0,

Henry Ford Hosp Med J—Vol 37, Nos 3 & 4, 1989

SMS 201-995 acute test
Two of the seven patients, both affected by sporadic MTC,
had a marked decrease of seram CT levels (patient A; baseline
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Fig2—Calcitonin responses to chronic SMS 201-995 administration (arrowhead indicates SMS 201-995 administration,
100 p,g subcutaneously; dotted line indicates pretreatment calcitonin levels; solid line indicates calcitonin levels after 90-day
treatment period with SMS 201-995, 300 [iglday).
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Fig 1—Comparison of calcitonin levels in an acute test with
SMS 201-995,100 [Lg subcutaneously, and saline infusion in two
responders (solid circle indicates patient A, triangle indicates
patient B, dotted Une indicates saline infusion, solid line indicates SMS 201-995 administration).
565 pglmL, nadir at 6 hrs 150 pglmL; patient B; baseline 1,632
pglmL, nadir at 3 hrs 416 pglmL) (Fig 1), The otherfivepatients
showed no significant change in CT in comparison with saline
infusion,
SMS 201-995 chronic treatment
One pafient had a sustained progressive fall in plasma CT levels during the SMS 201-995 acute test. Before the start of
chronic treatment with SMS 201-995 (300 p-g/day), his CT
seram levets were persistently about 50% lower than pretreatment values. However, this patient's CT levels did not retum to
normal during long-term SMS 201-995 therapy (Fig 2). The
other patient's CT levels remained similar to the pretreatment
values, but the watery dianhea was absent even after discontinuing chronic therapy.

Discussion
Total thyroidectomy with excision of central lymph nodes is
indicated in MTC (9). Once residual tumor becomes palpable,
no present treatment is likely to be curative (10). In some patients
elevated CT levels may persist following total thyroidectomy
even in the absence of evident residual tumor (11). tn patients
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with metastatic MTC, radioactive iodine has been found to be of
no therapeutic value, and the effectiveness of external radiotherapy in these pafients is controversial (12,13). Somatostatin is
found in CT-containing parafollicular cefls or C-celts of the thyroid (14). Somatostatin does inhibit pentagastrin-stimulated CT
retease in some patients with MTC (5) and atso directiy inhibits
pancreatic exocrine and endocrine secrefion (15). In our study,
the acute administration of SMS 201-995 had no effect on
plasma CT in five of seven pafients; in these patients we suggest
that the somatostatin receptor in MTC cells may be tost or nonfunctional or the affinity of the analog for the receptor may differ
from that of native somatostatin. However, one patient with
MTC and unexplained watery dianhea, whose plasma PP, VIP,
and gastrin and urinary 5HIAA excretion were normal, had resolution of symptoms with chronic SMS 201-995 administration.
No changes in plasma PP or CT concentrations were observed.
The role of CT in production of watery dianhea has not been
established (16,17), and the retease of other peptides by MTC
may be a causative factor. The analog may have improved the
diarrhea by inhibiting gut responses directiy. Experimental studies have demonstrated that SMS 201-995 is a potent inhibitor of
the intestinal secretion evoked by bradykinin, prostaglandins,
and serotonin. The most likely explanation ofthe effects of SMS
201-995 is that it interferes with the adenylate cyctase-cyctic
AMP system (18). tn two of our seven patients the acute administration of SMS 201-995 provided a decrease in plasma CT levels. One of these patients was treated with 300 p-g/day of SMS
201-995 for three months. In this pafient a clear conetafion existed between the acute responsiveness of CT levels to a single
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administrafion of SMS 201-995 and the decrease of 8-hour CT
levels achieved during chronic treatment (Fig 2). The
therapeutic effect of SMS 201-995 may be mediated by a specific somatostatin receptor (19). These data suggest a possible
trial of radioiodinated octreotide (tyr-3-octreotide) for the localization of MTC tumors (20).
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